ranibizumab

  • Purchase Qty: 1
  • Unit: g(s)
  • Fob Unit Price: US $3000
  • Production Capacity:20 kilogram per year
  • Payment Terms:L/C , T/T , D/P
  • Favorite
Shanghai TheraMabs Bio-technology co., LTD

Business Type:Manufacturer

Country/Region:China

Ddu Verified

HOT Rank

6/10

Product Information

Description

Purchase

Description

LUCENTIS® (ranibizumab) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

Ranibizumab is supplied at a concentration of 10 mg/mL as a sterile, colorless to pale yellow solution, which contains 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.

Properties

Name

Ranibizumab

CAS   NO.

347396-82-1

Type

Fab fragment

Source

Humanized (from mouse)

Target

VEGF-A

Clone

Monoclone

Molecular   Weight

48 kDa

Formula

C2158H3282N562O681S12

Antibody   Form

Purified immunoglobulin

Physical   Form

Solution

Grade   Standard

Medicine Grade

Place   of Origin

China(Mainland)

Storage

-70±15 for long-term   storage, 2-8   for short-term storage, away from light.

Supply Ability

20 kilogram per year, 1 GramMin. Order.

Material Safety Data Sheet

If you need more information, please contact us.

Certificate Of Analysis

If you need more information, please contact us.

 

Detail information about the product please refer the website below:

 

https://en.wikipedia.org/wiki/Ranibizumab

 


You Might Also Like
Change a group
Inquiry Cart(0)